MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage many intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal demo goals had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, while one of many exploratory https://jamest009hsd2.tusblogos.com/profile